SCHEMBL2727664

SCHEMBL2727664

CC(C)(C)[Si](C)(C)OC[C@@H]1CCC(=O)N1C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
CYP2C19 P33261 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
HTR2C P28335 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2843333 1.00 SMN1; SMN2 (0.41) SMN1; SMN2CYP2C19NPC1RAB9AHTR2C
SCHEMBL30694003 0.83 PSEN1 (0.40)
SCHEMBL29185150 0.83 PSEN1 (0.40)
SCHEMBL29560191 0.81 SMN1; SMN2 (0.45) SMN1; SMN2CYP2C19NPC1RAB9A
SCHEMBL30693995 0.81 AGTR2 (0.40) SMN1; SMN2NPC1RAB9AHTR2C
SCHEMBL3742158 0.80 DUT (0.34)
SCHEMBL211191 0.80 DUT (0.34)
SCHEMBL6475389 0.80 PREP (0.49) NPSR1
SCHEMBL6475398 0.80 PREP (0.49) NPSR1
SCHEMBL6484219 0.80 PREP (0.49) NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522593-B2 Azacycloalkyl carbonyl cyclic amine compound ALIVEXIS, INC. (JP) 2026-01-13 US disclosed
US-20250163041-A1 AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND ALIVEXIS, INC. (JP) 2025-05-22 US disclosed
EP-4538264-A1 AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND Alivexis, Inc. (JP) 2025-04-16 EP disclosed
CN-119317620-A Azacycloalkyl carbonyl cyclic amine compounds 亚力维克希斯股份有限公司 2025-01-14 CN disclosed
WO-2023243601-A1 AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND モジュラス株式会社 2023-12-21 WO disclosed
US-8895582-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-11-25 US disclosed
US-8759374-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-06-24 US disclosed
US-8759374-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-06-24 US disclosed
US-20130053348-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2013-02-28 US disclosed
US-20130053348-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2013-02-28 US disclosed
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2012-05-31 US disclosed
US-8088793-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2012-01-03 US disclosed
US-20090275537-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275537-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 SMN1; SMN2 252/4885CYP2C19 2307/4885NPC1 4684/4885
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MYLK, MYH2, MYH10 SMN1; SMN2 252/4885CYP2C19 2307/4885NPC1 4684/4885
US-20250163041-A1 AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND NCF1, ELANE, MPO SMN1; SMN2 1890/4885CYP2C19 840/4885NPC1 732/4885
US-20130053348-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MYLK, MYH2, MYH10 SMN1; SMN2 252/4885CYP2C19 2307/4885NPC1 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.